Creon

ApprovedSmall molecule

AbbVie

Creon is one of 153 small molecule programs targeting Chronic Pancreatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

152

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PancreatitisActive, not recruiting

Diabetes MellitusActive, not recruiting

HypoglycemiaActive, not recruiting

Cystic FibrosisActive, not recruiting

Type 1 DiabetesActive, not recruiting

Exocrine Pancreatic InsufficiencyRecruiting

Chronic PancreatitisApproved

Active, not recruiting

Diabetes MellitusApproved

Active, not recruiting

HypoglycemiaPhase 1

Active, not recruiting

Cystic FibrosisPreclinical

Active, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

Exocrine Pancreatic InsufficiencyPhase 2

Recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Creon

AbbVie

Approved

3 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 5

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Aztreonam Lysine

Gilead

Preclinical

5 7

Amitiza

SSucampo Pharma Americas, LLC

Preclinical

1 8

Capromorelin

UUniversity of Aarhus

Preclinical

1 9

Advil

KKenvue Brands

Preclinical

1 10

Tums

Otsuka

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Exocrine Pancreatic Insufficiency

NCT07450547

Clinical

Trials by Indication[1]

Chronic Pancreatitis4 trials

Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis

Completed·—·Phase 4·NCT00957151·12 enrolled

Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer

Withdrawn· AbbVie logo

AbbVie·Phase 4·NCT04315311

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Completed· AbbVie logo

AbbVie·Phase 4·NCT05069597·30 enrolled

Show 1 more trial

Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis

Completed·IInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement·N/A·NCT01154608·11 enrolled

Cystic Fibrosis3 trials

A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Completed·AAbbott·Phase 3·NCT02137382·41 enrolled

Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Completed·AAbbott·Phase 2·NCT02415959·70 enrolled

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Terminated· AbbVie logo

AbbVie··NCT01652157·17 enrolled

Exocrine Pancreatic Insufficiency2 trials

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

Completed· AbbVie logo

AbbVie··NCT04949828·63 enrolled

A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Recruiting·AAnagram Therapeutics, Inc.·Phase 2·NCT07450547·113 enrolled

Hypoglycemia1 trial

CREON for the Treatment of Post-RYGB Hypoglycemia

Terminated·—·Phase 1·NCT02733848·5 enrolled

Pancreatic Surgery1 trial

Creon After Pancreatic Surgery

Completed·AAbbott Products·Phase 4·NCT00535756·58 enrolled

3 more indications

Diabetes Mellitus1 trial

A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2

Withdrawn·AAbbott·Phase 4·NCT02009410

Type 1 Diabetes1 trial

Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes

Completed·VVanderbilt University Medical Center·Phase 1·NCT05266963·11 enrolled

Pancreatic1 trial

Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase

Terminated·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT01865695·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Creon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Creon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Creon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Creon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Chronic Pancreatitis4 trials

Cystic Fibrosis3 trials

Exocrine Pancreatic Insufficiency2 trials

Hypoglycemia1 trial

Pancreatic Surgery1 trial

Diabetes Mellitus1 trial

Type 1 Diabetes1 trial

Pancreatic1 trial

References

Drug Info

Quick Facts

Related News